The role involves leading communications for vopimetostat, the company's lead PRMT5 inhibitor, covering data, regulatory milestones, and commercial launch.
Base: $216,000 - $324,000 USD; Bonus/Equity: Not specified; Benefits: Not specified
Must-have
Nice-to-have
Not specified